2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
[HTML][HTML] CT evaluation by artificial intelligence for atherosclerosis, stenosis and vascular morphology(CLARIFY): a multi-center, international study
Background Atherosclerosis evaluation by coronary computed tomography angiography
(CCTA) is promising for coronary artery disease (CAD) risk stratification, but time consuming …
(CCTA) is promising for coronary artery disease (CAD) risk stratification, but time consuming …
A coronary CT angiography radiomics model to identify vulnerable plaque and predict cardiovascular events
Background A noninvasive coronary CT angiography (CCTA)–based radiomics technique
may facilitate the identification of vulnerable plaques and patients at risk for future adverse …
may facilitate the identification of vulnerable plaques and patients at risk for future adverse …
Ischemia and no obstructive coronary arteries (INOCA): a narrative review
Myocardial ischemia with no obstructive coronary arteries (INOCA) is a chronic coronary
syndrome condition that is increasingly being recognized as a substantial contributor to …
syndrome condition that is increasingly being recognized as a substantial contributor to …
Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial
Abstract Background and Aims The aim of this study was to determine the prognostic value
of coronary computed tomography angiography (CCTA)–derived atherosclerotic plaque …
of coronary computed tomography angiography (CCTA)–derived atherosclerotic plaque …
Rapid plaque progression is independently associated with hyperglycemia and low HDL cholesterol in patients with stable coronary artery disease: a PARADIGM …
BACKGROUND: We assessed whether combinations of cardiometabolic risk factors
independently predict coronary plaque progression (PP) and major adverse cardiovascular …
independently predict coronary plaque progression (PP) and major adverse cardiovascular …
[HTML][HTML] Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement✰
In this clinical practice statement, we represent a summary of the current evidence and
clinical applications of cardiac computed tomography (CT) in evaluation of coronary artery …
clinical applications of cardiac computed tomography (CT) in evaluation of coronary artery …
Clinical implications of monogenic versus polygenic hypercholesterolemia: long‐term response to treatment, coronary atherosclerosis burden, and cardiovascular …
L D'Erasmo, I Minicocci, A Di Costanzo… - Journal of the …, 2021 - Am Heart Assoc
Background Familial hypercholesterolemia (FH) may arise from deleterious monogenic
variants in FH‐causing genes as well as from a polygenic cause. We evaluated the …
variants in FH‐causing genes as well as from a polygenic cause. We evaluated the …
Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19
A Scoccia, G Gallone, A Cereda, A Palmisano… - Atherosclerosis, 2021 - Elsevier
Background and aims The potential impact of coronary atherosclerosis, as detected by
coronary artery calcium, on clinical outcomes in COVID-19 patients remains unsettled. We …
coronary artery calcium, on clinical outcomes in COVID-19 patients remains unsettled. We …